Status In progress
Process FTA
ID number 1075

Provisional Schedule

Expected publication 20 June 2018

Project Team

Project lead Jo Ekeledo

Email enquiries

Consultees

Companies sponsors Janssen (guselkumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Society for Rheumatology
  Royal College of Physicians

Commentators

Comparator companies AbbVie (adalimumab, methotrexate)
  Celgene (apremilast)
  Eli Lilly (ixekizumab)
  Merck Sharp & Dohme (infliximab)
  Novartis Pharmaceuticals (ciclosporin, secukinumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
01 February 2018 Committee meeting
30 August 2017 In progress, Appraisal has started
30 August 2017 Invitation to participate
18 January 2017 This appraisal is being considered as a Fast Track Appraisal (FTA). If a positive recommendation is made through the FTA process, NHS England/commissioners have committed to providing funding for the technologies within 30 days of final guidance publication. For further information please refer to the process guide addendum.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance